DARA BioSciences, Inc. (Nasdaq: DARA) announced today that Dr. David J. Drutz, Chief Executive Officer, will provide a comprehensive update on the company’s products and pipeline at the
2012 BIO International Convention
in Boston later this month. DARA's presentation is part of the BIO Business Forum and is scheduled for 3:45 p.m. ET on Wednesday, June 20, Red Sox Room at the Boston Convention and Exhibition Center. DARA BioSciences focuses on oncology treatment and supportive care products.
Dr. Drutz will discuss the development and commercialization of DARA’s product portfolio, which includes Bionect
a topical treatment for skin irritation and burns associated with radiation therapy, introduced to the market June 6, 2012; Soltamox
, the first and only oral liquid formulation of tamoxifen, widely used in the treatment and prevention of breast cancer, on track for launch in 2012; and KRN5500, under development for the treatment of neuropathic pain in patients with cancer, a condition with no current adequate therapy.
Attendees will be able to arrange one-on-one meetings with DARA in advance through the conference website 2012 BIO International Convention at
The BIO International Convention is hosted by the
Biotechnology Industry Organization
(BIO) and is the preeminent biotechnology meeting worldwide. Presenters at the BIO Business Forum will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture.
About DARA BioSciences, Inc.
DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA sharpened its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox
is a novel oral liquid formulation of tamoxifen, a product used widely in the treatment and prevention of breast cancer. Soltamox
is the only FDA approved oral liquid version of tamoxifen and fulfills a vital clinical need for patients who cannot tolerate existing tablet formulations of this drug. DARA plans to begin marketing Soltamox
in the U.S. in the third quarter of 2012.
DARA has also obtained exclusive U.S. commercial rights from Innocutis Holdings, LLC for Bionect
(hyaluronic acid sodium salt, 0.2%) within the oncology and radiation oncology marketplace. Bionect is an FDA-cleared product indicated for the management of irritation of the skin as well as first and second degree burns. Bionect
is currently being promoted and sold by Innocutis in the dermatology market. DARA launched this product in Q2 2012.
DARA has obtained, in addition, the U.S. rights to gemcitabine, a widely used generic chemotherapeutic cancer drug, from Uman Pharma. The Abbreviated New Drug Application (ANDA) for gemcitabine is expected to be filed with the FDA later this year.